RTOG-0513: MGd Phase II Trial in Glioblastoma - RTOG-0513

This study has been completed; results from the trial were presented at the 2011 American Society of Therapeutic Radiology and Oncology Annual Meeting.

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

RTOG-0513: A Phase I/II Trial of Temozolomide, Motexafin Gadolinium, and 60 GY Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme

Purpose

This trial is studying the side-effects and best dose of motexafin gadolinium (MGd) when given together with temozolomide and radiation therapy and to evaluate the effects of the treatment regimen on overall and progression-free survival of patients with newly diagnosed supratentorial glioblastoma multiforme (GBM).